Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV
The BRIDGE HCV initiative encourages medical specialists, primary care clinicians, and substance use disorders (SUD)–services providers to actively expand treatment of chronic hepatitis C virus (HCV) infection to include individuals with recent or ongoing injection drug use. This can lead to substantial reductions in HCV prevalence and transmission, benefiting both the individual and the community. These benefits are especially effective when combined with harm-reduction interventions. Strong local HCV-care networks with structured collaboration further help build bridges to HCV-infected people who inject drugs (PWID) and allow these at-risk individuals access to highly effective direct-acting antiviral therapies. This 2-part educational series offers cutting-edge strategies for collaboratively reaching and treating HCV-positive PWID. Presenting the critical balance between clinical data and real-world experience and insights, these activities will give participants the opportunity to listen to nationally recognized HCV experts as they discuss these topics and offer hands-on tactics and practical resources to use in the clinical setting.
Jointly provided by Purdue University College of Pharmacy and Integritas Communications.
This activity is supported by independent educational grants from Gilead Sciences, Inc., and AbbVie, Inc.
Opportunities for Current and New HCV Treaters
credit amount 0.75
credit type CME